Pfizer Reports Results from P-III Trial of Abrysvo for Increased Risk for RSV Disease
Shots:
- The P-III (MONeT) study assesses the safety, tolerability & immunogenicity of Abrysvo vs PBO in adults at high risk of developing severe RSV-associated lower respiratory tract disease (LRTD). The study had 2 subgroups, subgroup A (n=681, 18 to 59yrs. with chronic conditions) & subgroup B (n=~200 immunocompromised adults, 18yrs. & above)
- The study reached its immunogenicity endpoints depicting non-inferior RSV-A & RSV-B subgroup neutralizing responses as compared to Abrysvo’s P-III (RENOIR) trial among adults (n=34,000) of 60yrs. & above who experienced vaccine’s efficacy
- Furthermore, individuals reached a four-fold increase in serum neutralizing titers for RSV-A and RSV-B 1mos. post Abrysvo vs pre-vaccination levels
Ref: Pfizer | Image: Pfizer
Related News:- Pfizer’s Abrysvo Receives EC’s Marketing Authorization to Protect Infants through Maternal Immunization and Older Adults from RSV
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
